Evidence map›Paper›PMID 36082359›Full record

ArticleOncotarget2022

Targeted elastin-like polypeptide fusion protein for near-infrared imaging of human and canine urothelial carcinoma.

Aayush Aayush, Saloni Darji, Deepika Dhawan, Alexander Enstrom, Meaghan M Broman, Muhammad T Idrees, Hristos Kaimakliotis, Timothy Ratliff, Deborah Knapp, David Thompson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Optimizing mRNA delivery with targeted elastin-like polypeptide-based LENN formulations: Insights into the endocytosis mechanism.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aayush AayushDepartment of Chemistry, Purdue University, Bindley Bioscience Center, West Lafayette, IN 47907, USA.
Saloni DarjiDepartment of Chemistry, Purdue University, Bindley Bioscience Center, West Lafayette, IN 47907, USA.
Deepika DhawanDepartment of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN 47907, USA.
Alexander EnstromDepartment of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN 47907, USA.
Meaghan M BromanPurdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47907, USA.
Muhammad T IdreesDepartment of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN 46202, USA.
Hristos KaimakliotisDepartment of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Timothy RatliffPurdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47907, USA.
Deborah KnappDepartment of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN 47907, USA.
David ThompsonDepartment of Chemistry, Purdue University, Bindley Bioscience Center, West Lafayette, IN 47907, USA.

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI David W Clapp · 1999 to 2026
$59.3M
Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI ANDREW D MESECAR · 1985 to 2026
$43.4M
NCI NIH HHS P30 CA023168NCI NIH HHS P30 CA082709
6 · The paper itself

Abstract

Cystoscopic visualization of bladder cancer is an essential method for initial bladder cancer detection and diagnosis, transurethral resection, and monitoring for recurrence. We sought to develop a new intravesical imaging agent that is more specific and sensitive using a polypeptide based NIR (near-infrared) probe designed to detect cells bearing epidermal growth factor receptors (EGFR) that are overexpressed in 80% of urothelial carcinoma (UC) cases. The NIR imaging agent consisted of an elastin like polypeptide (ELP) fused with epidermal growth factor (EGF) and conjugated to Cy5.5 to give Cy5.5-N24-EGF as a NIR contrast agent. In addition to evaluation in human cells and tissues, the agent was tested in canine cell lines and tissue samples with naturally occurring invasive UC. Flow cytometry and confocal microscopy were used to test cell-associated fluorescence of the probe in T24 human UC cells, and in K9TCC-SH (high EGFR expression) and K9TCC-Original (low EGF expression) canine cell lines. The probe specifically engages these cells through EGFR within 15 min of incubation and reached saturation within a clinically relevant 1 h timeframe. Furthermore,

Indexed as

Carcinoma, Transitional CellRecombinant Fusion ProteinsUrinary Bladder NeoplasmsAnimalsCarbocyaninesCell Line, TumorContrast MediaDogsElastinEpidermal Growth FactorErbB ReceptorsHumansMiceMice, NudePeptidesCarbocyaninesContrast MediaCY5.5 cyanine dyeElastinEpidermal Growth FactorErbB ReceptorsPeptidesRecombinant Fusion Proteinsbladder cancerelastin-like polypeptideepidermal growth factor receptor (EGFR)NIR imagingtranslational studies

Identifiers

PMID36082359
PMCPMC9447490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.